Rotavirus Vaccine Safety

Key points

You can protect against rotavirus disease with vaccination.

Overview

Rotavirus is a contagious virus that can cause gastroenteritis (inflammation of the stomach and intestines).

The rotavirus vaccine is effective at preventing rotavirus disease.

Available vaccines & manufacturer package inserts

  • The FDA approved in 2008 for use in infants 6 to 24 weeks of age.
  • The FDA approved in 2006 for use in infants 6 to 32 weeks of age

Who should & should not get the vaccine

Most babies who get rotavirus vaccine do not have any problems with it.

Common side effects

  • Irritability.
  • Mild, temporary diarrhea or vomiting.

Some studies suggest that rotavirus vaccination possibly causes a small increase in the risk of intussusception, a type of bowel blockage. This side effect is very rare.

Vaccines, like any medicine, can have side effects. Most babies who get rotavirus vaccine do not have any problems with it.

Report possible adverse events to VAERS‎

The Vaccine Adverse Event Reporting System (VAERS) is an early warning system, co-managed by ÐÇ¿ÕÓéÀÖ¹ÙÍø and FDA, that monitors for potential vaccine safety problems. Healthcare providers and vaccine manufacturers are required by law to report certain adverse events (any side effect or health problem after vaccination that is concerning to you, even if you are not sure if the vaccine caused the event) following vaccination to VAERS; patients and caregivers can also submit reports.

A closer look at the safety data

Studies from the United States and other countries show a small increased risk of intussusception following rotavirus vaccination. About 1 in 20,000 US infants to 1 in 100,000 US infants who get rotavirus vaccine might develop intussusception within a week of getting the vaccine. This means that between 40 and 120 U.S. infants might develop intussusception related to rotavirus vaccine each year.

How ÐÇ¿ÕÓéÀÖ¹ÙÍø monitors vaccine safety

ÐÇ¿ÕÓéÀÖ¹ÙÍø and FDA are committed to monitoring the safety of vaccines. Once vaccines are licensed or authorized by FDA for use in the United States, ÐÇ¿ÕÓéÀÖ¹ÙÍø, FDA, and other federal agencies work together to monitor them using several safety systems.

Resources

  • Salmon DA, Lamber PH, Nohynek HM, Gee J, Parashar UD, Tate JE, Wilder-Smith A, Hartigan-Go KY, Smith PG, Zuber PLF. BMJ Glob Health. 2021 May;6(Suppl 2):e003814. Epub ahead of print.
  • Glanz JM, Clarke CL, Xu S, Daley MF, Shoup JA, Schroeder EB, Lewin BL, McClure DL, Kharbanda E, Klein NP, DeStefano F. JAMA Pediatr. 2020 May 1;174(5):455-462. Epub 2020 Mar 9.
  • Payne DC, Baggs J, Klein NP, Parashar UD. Clin Infect Dis. 2015 Jan 1;60(1):163-4.
  • Tate JE, Curns AT, Cortese MM, Weintraub ES, Hambidge S, Zangwill KM, et al. . Pediatrics. 2009;123(3):744-749.
  • Clayton HA, Cortes MM, Payne DC, Bartlett DL, Zimmerman LA, Williams WG, et al. Rotavirus vaccination coverage and adherence to the Advisory Committee on Immunization Practices (ACIP)-recommended vaccination schedule–United States, February 2006-May 2007. MMWR. 2008;57(15):398-401.
  • Chang EJ, Zangwill KM, Lee H, Ward JI. . Pediatr Infect Dis J. 2002;21(2):97-102.
  • Kramarz P, France EK, DeStefano F, Black SB, Shinefield H, Ward JI, et al. . Pediatr Infect Dis J. 2001;20(4):410-416.
  • Yen C, Jakob K, Hittier X, Gentsch J, LaRussa P, for the Clinical Immunization Safety Assessment (CISA) Network. . Vaccine. 2011May 31;29(24):4151-5.
  • Belongia, E. A., Irving, S. A., Shui, I. M., Kulldorff, M., Lewis, E., Yin, R., Lieu, T. A., Weintraub, E., Yih, W. K., Li, R., Baggs, J., & Vaccine Safety Datalink Investigation Group (2010). Real-time surveillance to assess risk of intussusception and other adverse events after pentavalent, bovine-derived rotavirus vaccine. The Pediatric infectious disease journal, 29(1), 1–5.
  • Buttery, J. P., Danchin, M. H., Lee, K. J., Carlin, J. B., McIntyre, P. B., Elliott, E. J., Booy, R., Bines, J. E., & PAEDS/APSU Study Group (2011). Intussusception following rotavirus vaccine administration: post-marketing surveillance in the National Immunization Program in Australia. Vaccine, 29(16), 3061–3066.
  • Carlin, J. B., Macartney, K. K., Lee, K. J., Quinn, H. E., Buttery, J., Lopert, R., Bines, J., & McIntyre, P. B. (2013). Intussusception risk and disease prevention associated with rotavirus vaccines in Australia's National Immunization Program. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 57(10), 1427–1434.
  • Centers for Disease Control and Prevention. Addition of history of intussusception as a contraindication for rotavirus vaccination. MMWR. 2011 Oct 21;60(41):1427.
  • Haber P, Patel M, Inzurieta HS, Baggs J, Gagiullo P, et al. Pediatrics. 2008 Jun;121(6):1206-12.
  • Haber P, Patel M, Pan Y, Baggs J, Haber M, et al. . Pediatrics. 2013 Jun;131(6):1042-9.
  • Hibbs BF, Miller ER, Shimabukuro T. Notes from the field: Rotavirus vaccine administration errors- United States, 2006-2013. MMWR. 2014 Jan 31;63(4):81.
  • Patel MM, Haber P, Baggs J, Zuber P, Bines JE, et al. Expert Rev Vaccines. 2009;8(11):1555-1564.
  • Patel MM, López-Collada VR, Bulhões MM, De Oliveira LH, Bautista Márquez A, et al. N Engl J Med. 2011 Jun 16;364(24):2283-92.
  • Shui IM, Baggs J, Patel M, Parashar UD, Rett M, et al. . JAMA. 2012 Feb 8;307(6):598-604.
  • Tate JE, Simonsen L, Viboud C, Steiner C, Patel MM, et al. . Pediatrics. 2008 May;121(5):e1125-32.
  • Weintraub ES, Baggs J, Duffy J, Vellozzi C, Belongia EA, et al. N Engl J Med. 2014 Feb 6; 370(6):513-9.
  • Yih WK, Lieu TA, Kulldorff M, Martin D, McMahill-Walraven CN, et al. . N Engl J Med. 2014 Feb 6;370(6):503-12.